上QQ阅读APP看书，第一时间看更新
参考文献
1.郭利涛，刘昱，王雪，等.利奈唑胺治疗糖肽类药物治疗无效的MRSA感染分析.中国抗生素杂志，2012，37（2）：149-152.
2.ChoiG，Gomersall CD，Tian Q，et al.Principles of antibacterial dosing in continuous renal replacement therapy.Crit Care Med，2009，37：2268-2282.
3.Baptista JP，Udy AA，Sousa E，et al.A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance.Crit Care，2011，15：R139.
4.李文雄.脓毒症患者抗菌药物的个体化治疗.中国感染与化疗杂志，2016，16（4）：515-519.
5.Claus Bo，Hostr EA，Colpaert K，et al.Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.JCrit Care，2013，28：695-700.
6.Carlier M，Carrette S，Roberts JA，et al.Meropenem and piperacillin/tazobactam prescribing in critically ill patients：does augmented renal clearance affect pharmacokinetic and pharmacodynamic target attainmentwhen extended infusions are used？Crit Care，2013，17：R84.
7.Udy AA，Roberts JA，Shorr AF，et al.Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations：identifying at-risk patients.Crit Care，2013，17：R35.
8.Li AM，Gomersall CD，Choi G，et al.A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy：do current studies supply sufficient data？JAntimicrob Chemother，2009，5：929-937.
9.Trotman RL，Williamson JC，Shoemaker DM，et al.Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.Clin Infect Dis，2005，41：1159-1166.
10.KDIGO Clinical practice guidelin for acute kidney injury.Kidney Int，2012，（Suppl）2：1-138.
11.Matzke GR，Aronoff GR，Atkinson Jr AJ，etal.Drug dosing consideration in patientswith acute and chronic kidney disease—a clinical update from Kidney Disease：Improving Global Outcomes（KDIGO）.Kidney Int，2011，80：1122-1137.
12.Pea F，Viale P.Bench-to-bedside review：Appropriate antibiotic therapy in severe sepsis and septic shock-does the dosematter？Crit Care，2009，13：214-237.
13.Roberts BM，Liu X，Roberts JA，etal.A multicenter study on the effectof continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Crit Care，2015，19：84.
14.Zander J，Döbbeler G，Nagel D，et al.Piperacillin concentration in relation to therapeutic range in critically ill patients-a prospective observational study.Crit Care，2016，20：79.
15.Wagner BK，O'Hara DA.Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.Clin Pharmacokinet，1997，33：426-453.
16.Kirwan CJ，MacPhee IA，Lee T，et al.Acute kidney injury reduces the hepaticmetabolism of midazolam in critically ill patients.Intensive Care Med，2012，38：76-84.
17.Kirwan CJ，Lee T，Holt DW，et al.Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients.Intensive Care Med，2009，35：1271-1275.
18.Yogaratnam D，Miller MA，Smith BS.The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in thecritically ill patient.Crit Care Nurs Clin N Am，2005，17：245-250.
19.Milne RW，Nation RL，Somogyi AA，et al.The influence of renal function on the renal clearance of morphine and its glucuronidemetabolites in intensive-care patients.Br Jclin Pharmac，1992，34：53-59.
20.De Wolf AM，Fragen RJ，Avram MJ，et al.The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment.Anesth Analg，2001，93：1205-1209.
21.Breen D，Wilmer A，Bodenham A，et al.Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment.Crit Care，2004，8：R21-30.
22.Wilhelm W，Kreuer S.The place for short-acting opioids：special emphasis on remifentanil.Crit Care，2008，12（Suppl 3）：S5.
23.Power BM，Forbes AM，Heerden PV，et al.Pharmacokinetics of drugs used in critically ill adults.Clin Pharmacokinet，1998，34：25-56.
24.Niscola P，Scaramucci L，VischiniG，et al.The use ofmajor analgesics in patientswith renal dysfunction.Current Drug Targets，2010，11：752-758.
25.Anger KE.Dexmedetomidine：A review of its use for the management of pain，agitation，and delirium in the intensive care unit.Current Pharmaceutical Design，2013，19：4003-4013.
26.Karambelkar A，Kasekar R，Palevsky PM.Perioperative pharmacologic management of patients with end stage renal disease.Seminars in Dialysis，2015，8：392-396.